ClinicalTrials.gg
CompletedNCT00962780Updated Nov 17, 2014Results posted

Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) and 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in HIV Infections and Pneumococcal Infections, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2014-11-17.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
303
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in HIV Infections by Pfizer — none open to participants now, none under way, none of them phase 3. HIV Infections · Pfizer.

Enrollment
8th of 28
303 · median 160
Started
2010
with 1 other
Phase 3
10 of 65
none open now
Registered
63rd of 65
by date

Among the 65 studies in HIV Infections by Pfizer, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2010, is one of 10 in phase 3, and was the 63rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 65 studies in HIV Infections by Pfizer is open now. The open studies under HIV Infections, anywhere →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 65 studies in HIV Infections by Pfizer as a file.
02

Study summary

The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who have not been previously immunized with a pneumococcal vaccine. All subjects will receive 3 doses of 13vPnC and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS), with each dose given approximately 1 month apart.

03

Conditions studied

  • HIV Infections
  • Pneumococcal Infections

Keywords

  • vaccine
  • 13-valent pneumococcal conjugate vaccine
  • 23-valent pneumococcal polysaccharide vaccine
  • human immunodeficiency virus
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (HIV)-infected subjects aged 6 years or older
  • Viral load \< 50,000 copies/mL and >= 200/uL within 6 months before study vaccination
  • Receiving stable highly active antiretroviral therapy (HAART) or not currently receiving any antiretroviral therapy
  • No previous vaccination with a pneumococcal vaccine
  • Subject or parent/legal guardian able to complete an electronic diary

Exclusion criteria

Exclusion Criteria:

  • Acquired immune deficiency syndrome (AIDS) at time of enrollment
  • Current illicit substance and/or alcohol abuse
  • History of active chronic viral hepatitis
  • Previous anaphylactic reaction to a vaccine or vaccine-related component
  • Serious chronic disorders including and end-stage renal disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    1

    3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart

    Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC) · Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) · Procedure: Blood draw

Interventions

  • 13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3

  • Biological23-valent Pneumococcal Polysaccharide Vaccine (23vPS)

    23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)

  • ProcedureBlood draw

    Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).

  • ProcedureBlood draw

    1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.

    Also known as: Screening blood draw(s)

06

What researchers measure

Primary outcomes

  1. Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.

    Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3

Secondary outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3

  2. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3

  3. Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.

    Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3

  4. Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.

    Time frame: 1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3

Other outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1

  2. Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.

    Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1

  3. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1

  4. Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.

    Time frame: Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1

  5. Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose

  6. Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.

    Time frame: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose

  7. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a mcOPA assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose

  8. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.

    Time frame: 1 month after 13vPnC Dose 3, 1 month after 23vPS Dose

  9. Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters (cm) for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged greater than (\>) 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Report of severe swelling was confirmed as data entry error.

    Time frame: Within 14 days after 13vPnC Dose 1

  10. Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

    Time frame: Within 14 days after 13vPnC Dose 2

  11. Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

    Time frame: Within 14 days after 13vPnC Dose 3

  12. Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1

    Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C except 2 participants and all reporting of severe vomiting, after 13vPnC Dose 1, were confirmed as data entry errors.

    Time frame: Within 14 days after 13vPnC Dose 1

  13. Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2

    Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C and all reporting of severe vomiting, after 13vPnC Dose 2, were confirmed as data entry errors.

    Time frame: Within 14 days after 13vPnC Dose 2

  14. Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3

    Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C except 1 participant and all reporting of severe vomiting, after 13vPnC Dose 3, were confirmed as data entry errors.

    Time frame: Within 14 days after 13vPnC Dose 3

07

Results

Posted Nov 17, 2014

Participant flow

Participant flow — Overall Study
Milestone13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)
Started151152
Vaccinated 13vpnc dose 1150151
Vaccinated 13vpnc dose 2145145
Vaccinated 13vpnc dose 3144142
Vaccinated 23vps dose143139
Completed141138
Not completed1014
Withdrew: Death01
Withdrew: Protocol violation94
Withdrew: Withdrawal by subject18
Withdrew: Other01

Outcome measures

PrimaryGeometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.

Time frame:
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants
fold rise13vPnC, 23vPS (All Participants)
Serotype 1 (n = 248)1.03 (0.99 to 1.07)
Serotype 3 (n = 238)1.05 (1.00 to 1.10)
Serotype 4 (n = 257)1.09 (1.03 to 1.14)
Serotype 5 (n = 257)1.01 (0.97 to 1.05)
Serotype 6A (n = 249)1.02 (0.97 to 1.07)
Serotype 6B (n = 257)1.04 (1.01 to 1.08)
Serotype 7F (n = 259)1.10 (1.05 to 1.16)
Serotype 9V (n = 259)1.05 (1.01 to 1.09)
Serotype 14 (n = 259)1.04 (1.00 to 1.09)
Serotype 18C (n = 259)0.99 (0.96 to 1.02)
Serotype 19A (n = 259)0.99 (0.96 to 1.03)
Serotype 19F (n = 252)1.06 (1.01 to 1.11)
Serotype 23F (n = 258)1.09 (1.03 to 1.15)
SecondaryGeometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants
microgram per milliliter (mcg/mL)13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1: 13vPnC Dose 2 (n = 120, 128, 248)3.88 (3.30 to 4.57)3.95 (3.23 to 4.85)3.92 (3.44 to 4.46)
Serotype 1: 13vPnC Dose 3 (n = 120, 128, 248)4.14 (3.56 to 4.83)3.92 (3.21 to 4.79)4.03 (3.55 to 4.57)
Serotype 3: 13vPnC Dose 2 (n = 118, 120, 238)1.47 (1.25 to 1.74)0.97 (0.81 to 1.16)1.19 (1.05 to 1.35)
Serotype 3: 13vPnC Dose 3 (n = 118, 120, 238)1.49 (1.26 to 1.76)1.06 (0.88 to 1.27)1.25 (1.11 to 1.42)
Serotype 4: 13vPnC Dose 2 (n = 127, 130, 257)3.06 (2.54 to 3.69)2.97 (2.40 to 3.67)3.01 (2.62 to 3.47)
Serotype 4: 13vPnC Dose 3 (n = 127, 130, 257)3.36 (2.84 to 3.97)3.19 (2.59 to 3.91)3.27 (2.87 to 3.73)
Serotype 5: 13vPnC Dose 2 (n = 126, 131, 257)4.52 (3.78 to 5.39)5.77 (4.83 to 6.89)5.12 (4.51 to 5.80)
Serotype 5: 13vPnC Dose 3 (n = 126, 131, 257)4.84 (4.12 to 5.70)5.53 (4.63 to 6.61)5.18 (4.60 to 5.85)
Serotype 6A: 13vPnC Dose 2 (n = 119, 130, 249)7.66 (6.46 to 9.08)7.03 (5.71 to 8.67)7.33 (6.40 to 8.39)
Serotype 6A: 13vPnC Dose 3 (n = 119, 130, 249)7.97 (6.81 to 9.33)7.04 (5.74 to 8.64)7.47 (6.56 to 8.51)
Serotype 6B: 13vPnC Dose 2 (n = 127, 130, 257)11.43 (9.45 to 13.84)7.93 (6.51 to 9.65)9.50 (8.28 to 10.91)
Serotype 6B: 13vPnC Dose 3 (n = 127, 130, 257)11.94 (10.01 to 14.24)8.28 (6.78 to 10.11)9.92 (8.67 to 11.35)
Serotype 7F: 13vPnC Dose 2 (n = 128, 131, 259)4.25 (3.67 to 4.92)5.78 (4.81 to 6.95)4.96 (4.41 to 5.59)
Serotype 7F: 13vPnC Dose 3 (n = 128, 131, 259)5.05 (4.38 to 5.82)5.90 (4.95 to 7.04)5.46 (4.88 to 6.12)
Serotype 9V: 13vPnC Dose 2 (n = 128, 131, 259)4.81 (4.18 to 5.54)5.14 (4.27 to 6.19)4.98 (4.43 to 5.59)
Serotype 9V: 13vPnC Dose 3 (n = 128, 131, 259)4.98 (4.35 to 5.70)5.48 (4.59 to 6.55)5.23 (4.67 to 5.84)
Serotype 14: 13vPnC Dose 2 (n = 128, 131, 259)11.60 (8.76 to 15.35)15.14 (11.64 to 19.71)13.27 (10.96 to 16.08)
Serotype 14: 13vPnC Dose 3 (n = 128, 131, 259)12.62 (9.75 to 16.33)15.13 (11.80 to 19.40)13.83 (11.57 to 16.53)
Serotype 18C: 13vPnC Dose 2 (n = 128, 131, 259)3.79 (3.12 to 4.60)5.33 (4.34 to 6.54)4.50 (3.91 to 5.19)
Serotype 18C: 13vPnC Dose 3 (n = 128, 131, 259)3.83 (3.19 to 4.60)5.18 (4.27 to 6.28)4.46 (3.90 to 5.10)
Serotype 19A: 13vPnC Dose 2 (n = 128, 131, 259)14.38 (12.20 to 16.96)13.19 (11.06 to 15.75)13.77 (12.21 to 15.53)
Serotype 19A: 13vPnC Dose 3 (n = 128, 131, 259)14.19 (12.17 to 16.54)13.18 (11.11 to 15.62)13.67 (12.20 to 15.32)
Serotype 19F: 13vPnC Dose 2 (n = 124, 128, 252)5.78 (4.63 to 7.21)5.34 (4.17 to 6.84)5.55 (4.71 to 6.55)
Serotype 19F: 13vPnC Dose 3 (n = 124, 128, 252)6.09 (4.98 to 7.44)5.67 (4.47 to 7.18)5.87 (5.03 to 6.85)
Serotype 23F: 13vPnC Dose 2 (n = 127, 131, 258)6.45 (5.30 to 7.85)6.10 (4.86 to 7.66)6.27 (5.40 to 7.28)
Serotype 23F: 13vPnC Dose 3 (n = 127, 131, 258)6.64 (5.55 to 7.94)7.06 (5.65 to 8.82)6.85 (5.94 to 7.90)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Reported as:
Geometric mean · titers
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 Relative to 1 Month After 13vPnC Dose 2 in Pediatric, Adult and All Participants
titers13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1: 13vPnC Dose 2 (n = 126, 127, 253)51 (37.2 to 70.0)54 (38.7 to 74.2)52 (41.8 to 65.5)
Serotype 1: 13vPnC Dose 3 (n = 126, 127, 253)69 (51.6 to 91.4)69 (51.3 to 92.0)69 (56.1 to 84.1)
Serotype 3: 13vPnC Dose 2 (n = 127, 129, 256)81 (64.1 to 102.0)48 (37.9 to 61.5)62 (52.6 to 73.9)
Serotype 3: 13vPnC Dose 3 (n = 127, 129, 256)114 (94.5 to 137.8)79 (62.1 to 99.9)95 (81.3 to 110.3)
Serotype 4: 13vPnC Dose 2 (n = 117, 126, 243)2509 (1922.3 to 3274.2)1620 (1211.2 to 2167.4)2000 (1639.8 to 2439.1)
Serotype 4: 13vPnC Dose 3 (n = 117, 126, 243)3246 (2697.1 to 3906.3)1944 (1465.3 to 2579.7)2488 (2092.1 to 2959.8)
Serotype 5: 13vPnC Dose 2 (n = 122, 124, 246)159 (109.2 to 232.2)104 (69.1 to 156.9)129 (97.3 to 169.7)
Serotype 5: 13vPnC Dose 3 (n = 122, 124, 246)267 (191.3 to 371.5)142 (97.5 to 206.7)194 (150.8 to 249.7)
Serotype 6A: 13vPnC Dose 2 (n = 125, 124, 249)5560 (4378.4 to 7060.9)2425 (1790.7 to 3284.5)3678 (3016.2 to 4485.6)
Serotype 6A: 13vPnC Dose 3 (n = 125, 124, 249)7758 (6314.2 to 9531.2)3239 (2488.5 to 4215.9)5022 (4216.8 to 5979.9)
Serotype 6B: 13vPnC Dose 2 (n = 121, 128, 249)5449 (4365.1 to 6801.1)2724 (2004.8 to 3701.0)3815 (3140.9 to 4634.1)
Serotype 6B: 13vPnC Dose 3 (n = 121, 128, 249)7151 (5828.2 to 8773.9)3723 (2771.1 to 5002.5)5113 (4250.1 to 6150.5)
Serotype 7F: 13vPnC Dose 2 (n = 125, 127, 252)3494 (2772.8 to 4403.3)2255 (1739.6 to 2923.6)2802 (2352.6 to 3338.0)
Serotype 7F: 13vPnC Dose 3 (n = 125, 127, 252)4638 (3889.7 to 5529.4)2702 (2130.3 to 3428.2)3533 (3037.4 to 4108.5)
Serotype 9V: 13vPnC Dose 2 (n = 118, 127, 245)3339 (2461.4 to 4530.3)1432 (998.6 to 2054.9)2153 (1690.3 to 2743.3)
Serotype 9V: 13vPnC Dose 3 (n = 118, 127, 245)4714 (3731.5 to 5955.4)2004 (1416.5 to 2836.1)3026 (2434.3 to 3761.4)
Serotype 14: 13vPnC Dose 2 (n = 117, 127, 244)3704 (2906.5 to 4719.5)1342 (1010.1 to 1782.1)2183 (1792.2 to 2659.6)
Serotype 14: 13vPnC Dose 3 (n = 117, 127, 244)3963 (3195.8 to 4914.2)1480 (1150.3 to 1903.9)2373 (1988.4 to 2832.8)
Serotype 18C: 13vPnC Dose 2 (n = 117, 121, 238)4635 (3609.7 to 5951.8)1349 (947.0 to 1921.5)2475 (1965.7 to 3115.4)
Serotype 18C: 13vPnC Dose 3 (n = 117, 121, 238)5579 (4423.7 to 7036.9)1787 (1272.8 to 2508.5)3127 (2515.2 to 3888.6)
Serotype 19A: 13vPnC Dose 2 (n = 125, 127, 252)684 (519.2 to 902.1)458 (332.5 to 631.2)559 (452.3 to 690.9)
Serotype 19A: 13vPnC Dose 3 (n = 125, 127, 252)1002 (814.5 to 1232.3)613 (465.6 to 806.4)782 (657.2 to 930.5)
Serotype 19F: 13vPnC Dose 2 (n = 122, 118, 240)717 (495.6 to 1036.7)315 (196.7 to 506.0)479 (354.4 to 646.9)
Serotype 19F: 13vPnC Dose 3 (n = 122, 118, 240)1152 (864.2 to 1535.0)597 (397.9 to 897.1)834 (650.1 to 1070.2)
Serotype 23F: 13vPnC Dose 2 (n = 120, 126, 246)1477 (1086.2 to 2008.2)409 (271.9 to 614.0)765 (585.2 to 999.4)
Serotype 23F: 13vPnC Dose 3 (n = 120, 126, 246)2327 (1844.2 to 2935.9)671 (449.8 to 1000.3)1231 (963.0 to 1572.5)
SecondaryGeometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.

Time frame:
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n = 126, 127, 253)1.3 (1.13 to 1.61)1.3 (1.09 to 1.51)1.3 (1.16 to 1.48)
Serotype 3 (n = 127, 129, 256)1.4 (1.25 to 1.59)1.6 (1.45 to 1.83)1.5 (1.40 to 1.65)
Serotype 4 (n = 117, 126, 243)1.3 (1.10 to 1.52)1.2 (1.07 to 1.34)1.2 (1.13 to 1.37)
Serotype 5 (n = 122, 124, 246)1.7 (1.36 to 2.06)1.4 (1.17 to 1.59)1.5 (1.33 to 1.72)
Serotype 6A (n = 125, 124, 249)1.4 (1.22 to 1.60)1.3 (1.15 to 1.55)1.4 (1.23 to 1.51)
Serotype 6B (n = 121, 128, 249)1.3 (1.18 to 1.46)1.4 (1.20 to 1.56)1.3 (1.23 to 1.46)
Serotype 7F (n = 125, 127, 252)1.3 (1.15 to 1.53)1.2 (1.03 to 1.40)1.3 (1.14 to 1.40)
Serotype 9V (n = 118, 127, 245)1.4 (1.16 to 1.72)1.4 (1.18 to 1.65)1.4 (1.24 to 1.60)
Serotype 14 (n = 117, 127, 244)1.1 (0.95 to 1.20)1.1 (0.98 to 1.24)1.1 (1.00 to 1.18)
Serotype 18C (n = 117, 121, 238)1.2 (1.10 to 1.32)1.3 (1.08 to 1.63)1.3 (1.13 to 1.42)
Serotype 19A (n = 125, 127, 252)1.5 (1.27 to 1.68)1.3 (1.18 to 1.52)1.4 (1.27 to 1.54)
Serotype 19F (n = 122, 118, 240)1.6 (1.31 to 1.97)1.9 (1.45 to 2.48)1.7 (1.48 to 2.06)
Serotype 23F (n = 120, 126, 246)1.6 (1.31 to 1.90)1.6 (1.34 to 2.02)1.6 (1.40 to 1.85)
SecondaryGeometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 2 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 2 and after 13vPnC Dose 3 blood draws.

Time frame:
1 month after 13vPnC Dose 2, 1 month after 13vPnC Dose 3
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)
Serotype 1 (n = 120, 128)1.07 (1.01 to 1.13)0.99 (0.93 to 1.06)
Serotype 3 (n = 118, 120)1.01 (0.95 to 1.08)1.09 (1.02 to 1.16)
Serotype 4 (n = 127, 130)1.10 (1.02 to 1.18)1.07 (1.00 to 1.16)
Serotype 5 (n = 126, 131)1.07 (1.01 to 1.14)0.96 (0.91 to 1.01)
Serotype 6A (n = 119, 130)1.04 (0.96 to 1.12)1.00 (0.95 to 1.06)
Serotype 6B (n = 127, 130)1.04 (0.99 to 1.10)1.04 (0.99 to 1.11)
Serotype 7F (n = 128, 131)1.19 (1.12 to 1.27)1.02 (0.95 to 1.10)
Serotype 9V (n = 128, 131)1.03 (0.98 to 1.09)1.07 (1.02 to 1.12)
Serotype 14 (n = 128, 131)1.09 (1.02 to 1.16)1.00 (0.95 to 1.05)
Serotype 18C (n = 128, 131)1.01 (0.96 to 1.07)0.97 (0.93 to 1.01)
Serotype 19A (n = 128, 131)0.99 (0.93 to 1.04)1.00 (0.96 to 1.04)
Serotype 19F (n = 124, 128)1.05 (0.98 to 1.13)1.06 (0.99 to 1.14)
Serotype 23F (n = 127, 131)1.03 (0.96 to 1.11)1.16 (1.07 to 1.26)
Other pre-specifiedGeometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
mcg/mL13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1: Before 13vPnC Dose 1 (n=78,122,200)1.03 (0.72 to 1.48)0.82 (0.63 to 1.06)0.90 (0.73 to 1.10)
Serotype 1: After 13vPnC Dose 1 (n=78,122,200)3.78 (2.97 to 4.80)4.00 (3.19 to 5.01)3.91 (3.32 to 4.61)
Serotype 3: Before 13vPnC Dose 1 (n=99,127,226)0.83 (0.62 to 1.11)0.47 (0.37 to 0.58)0.60 (0.50 to 0.72)
Serotype 3: After 13vPnC Dose 1 (n=99,127,226)1.25 (0.99 to 1.58)0.75 (0.62 to 0.92)0.94 (0.81 to 1.09)
Serotype 4: Before 13vPnC Dose 1 (n=95,127,222)0.19 (0.14 to 0.25)0.35 (0.28 to 0.45)0.27 (0.22 to 0.33)
Serotype 4: After 13vPnC Dose 1 (n=95,127,222)2.62 (1.97 to 3.50)2.91 (2.26 to 3.75)2.79 (2.31 to 3.36)
Serotype 5: Before 13vPnC Dose 1 (n=122,137,259)4.18 (3.42 to 5.12)3.38 (2.84 to 4.02)3.74 (3.28 to 4.27)
Serotype 5: After 13vPnC Dose 1 (n=122,137,259)4.81 (3.98 to 5.80)5.53 (4.63 to 6.61)5.18 (4.55 to 5.89)
Serotype 6A: Before 13vPnC Dose 1 (n=99,136,235)6.22 (5.19 to 7.45)2.67 (2.24 to 3.18)3.81 (3.32 to 4.37)
Serotype 6A: After 13vPnC Dose 1 (n=99,136,235)7.31 (6.07 to 8.79)6.77 (5.38 to 8.51)6.99 (6.00 to 8.15)
Serotype 6B: Before 13vPnC Dose 1 (n=131,134,265)5.52 (4.59 to 6.64)3.23 (2.69 to 3.88)4.21 (3.69 to 4.81)
Serotype 6B: After 13vPnC Dose 1 (n=131,134,265)10.26 (8.37 to 12.58)7.29 (5.81 to 9.15)8.63 (7.41 to 10.06)
Serotype 7F: Before 13vPnC Dose 1 (n=111,134,245)0.85 (0.63 to 1.14)1.14 (0.94 to 1.37)1.00 (0.84 to 1.18)
Serotype 7F: After 13vPnC Dose 1 (n=111,134,245)4.34 (3.68 to 5.11)5.57 (4.57 to 6.78)4.97 (4.36 to 5.67)
Serotype 9V: Before 13vPnC Dose 1 (n=129,137,266)2.10 (1.74 to 2.54)1.56 (1.30 to 1.86)1.80 (1.58 to 2.05)
Serotype 9V: After 13vPnC Dose 1 (n=129,137,266)4.77 (4.08 to 5.57)5.16 (4.24 to 6.27)4.97 (4.38 to 5.63)
Serotype 14: Before 13vPnC Dose 1 (n=113,136,249)0.76 (0.57 to 1.03)2.45 (1.94 to 3.09)1.44 (1.18 to 1.76)
Serotype 14: After 13vPnC Dose 1 (n=113,136,249)12.04 (8.48 to 17.10)16.46 (12.38 to 21.90)14.28 (11.44 to 17.84)
Serotype 18C: Before 13vPnC Dose 1 (n=127,134,261)0.66 (0.52 to 0.85)0.85 (0.69 to 1.04)0.75 (0.64 to 0.88)
Serotype 18C: After 13vPnC Dose 1 (n=127,134,261)3.92 (3.14 to 4.91)5.55 (4.51 to 6.84)4.69 (4.02 to 5.46)
Serotype 19A: Before 13vPnC Dose 1 (n=133,137,270)7.51 (6.34 to 8.90)4.78 (4.04 to 5.66)5.97 (5.29 to 6.74)
Serotype 19A: After 13vPnC Dose 1 (n=133,137,270)13.28 (11.11 to 15.87)13.03 (10.75 to 15.80)13.15 (11.54 to 14.99)
Serotype 19F: Before 13vPnC Dose 1 (n=93,126,219)1.36 (1.06 to 1.75)1.36 (1.07 to 1.73)1.36 (1.14 to 1.62)
Serotype 19F: After 13vPnC Dose 1 (n=93,126,219)4.62 (3.55 to 6.02)4.98 (3.74 to 6.62)4.82 (3.96 to 5.88)
Serotype 23F: Before 13vPnC Dose 1 (n=126,137,263)2.29 (1.83 to 2.86)1.61 (1.31 to 1.96)1.90 (1.64 to 2.21)
Serotype 23F: After 13vPnC Dose 1 (n=126,137,263)5.65 (4.66 to 6.86)5.30 (4.16 to 6.75)5.47 (4.68 to 6.39)
Other pre-specifiedGeometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.

Time frame:
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n = 78, 122, 200)3.67 (2.70 to 4.99)4.88 (3.87 to 6.15)4.37 (3.63 to 5.25)
Serotype 3 (n = 99, 127, 226)1.51 (1.27 to 1.79)1.62 (1.43 to 1.83)1.57 (1.42 to 1.74)
Serotype 4 (n = 95, 127, 222)14.02 (10.55 to 18.62)8.29 (6.55 to 10.49)10.38 (8.64 to 12.47)
Serotype 5 (n = 122, 137, 259)1.15 (1.06 to 1.25)1.64 (1.44 to 1.85)1.38 (1.28 to 1.50)
Serotype 6A (n = 99, 136, 235)1.18 (1.02 to 1.35)2.54 (2.09 to 3.07)1.83 (1.60 to 2.10)
Serotype 6B (n = 131, 134, 265)1.86 (1.55 to 2.22)2.26 (1.87 to 2.72)2.05 (1.80 to 2.33)
Serotype 7F (n = 111, 134, 245)5.11 (3.92 to 6.65)4.90 (3.99 to 6.03)4.99 (4.24 to 5.88)
Serotype 9V (n = 129, 137, 266)2.27 (1.97 to 2.61)3.32 (2.76 to 3.99)2.76 (2.45 to 3.10)
Serotype 14 (n = 113, 136, 249)15.79 (11.84 to 21.05)6.73 (5.17 to 8.76)9.91 (8.11 to 12.11)
Serotype 18C (n = 127, 134, 261)5.92 (4.64 to 7.55)6.55 (5.23 to 8.20)6.23 (5.29 to 7.35)
Serotype 19A (n = 133, 137, 270)1.77 (1.55 to 2.02)2.73 (2.31 to 3.21)2.20 (1.98 to 2.45)
Serotype 19F (n = 93, 126, 219)3.39 (2.71 to 4.25)3.66 (2.96 to 4.52)3.54 (3.04 to 4.13)
Serotype 23F (n = 126, 137, 263)2.47 (2.02 to 3.02)3.30 (2.71 to 4.03)2.87 (2.49 to 3.31)
Other pre-specifiedSerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both the before and after 13vPnC Dose 1 blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Reported as:
Geometric mean · titers
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
titers13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1: Before 13vPnC Dose 1 (n=129,127,256)5 (4.3 to 5.8)5 (4.3 to 5.2)5 (4.4 to 5.3)
Serotype 1: After 13vPnC Dose 1 (n=129,127,256)49 (35.3 to 68.1)57 (41.6 to 79.3)53 (42.2 to 66.7)
Serotype 3: Before 13vPnC Dose 1 (n=126,128,254)8 (6.6 to 10.8)5 (4.5 to 5.8)7 (5.7 to 7.5)
Serotype 3: After 13vPnC Dose 1 (n=126,128,254)41 (31.7 to 52.6)21 (16.3 to 27.1)29 (24.3 to 35.1)
Serotype 4: Before 13vPnC Dose 1 (n=108,119,227)25 (15.2 to 41.7)27 (17.0 to 42.1)26 (18.6 to 36.3)
Serotype 4: After 13vPnC Dose 1 (n=108,119,227)2247 (1611.9 to 3131.4)1372 (958.8 to 1963.7)1735 (1356.9 to 2218.3)
Serotype 5: Before 13vPnC Dose 1 (n=125,122,247)5 (4.5 to 6.7)6 (4.8 to 6.8)6 (4.9 to 6.4)
Serotype 5: After 13vPnC Dose 1 (n=125,122,247)79 (52.5 to 118.0)123 (81.8 to 186.3)98 (73.7 to 131.1)
Serotype 6A: Before 13vPnC Dose 1 (n=99,98,197)157 (84.4 to 292.5)61 (35.1 to 106.8)98 (64.6 to 149.4)
Serotype 6A: After 13vPnC Dose 1 (n=99,98,197)3480 (2460.1 to 4921.8)1543 (984.4 to 2418.5)2322 (1743.1 to 3092.9)
Serotype 6B: Before 13vPnC Dose 1 (n=101,120,221)279 (155.5 to 501.1)231 (143.4 to 372.5)252 (174.1 to 364.6)
Serotype 6B: After 13vPnC Dose 1 (n=101,120,221)3852 (2888.3 to 5137.8)2099 (1455.6 to 3028.2)2771 (2179.2 to 3522.5)
Serotype 7F: Before 13vPnC Dose 1 (n=110,113,223)416 (253.5 to 682.9)38 (22.9 to 64.6)124 (84.3 to 183.8)
Serotype 7F: After 13vPnC Dose 1 (n=110,113,223)3775 (3019.4 to 4720.1)2005 (1443.9 to 2783.1)2739 (2237.5 to 3353.5)
Serotype 9V: Before 13vPnC Dose 1 (n=109,117,226)152 (87.2 to 266.2)69 (40.7 to 117.2)101 (68.8 to 148.6)
Serotype 9V: After 13vPnC Dose 1 (n=109,117,226)2533 (1822.7 to 3520.3)1231 (836.1 to 1812.2)1743 (1347.0 to 2256.4)
Serotype 14: Before 13vPnC Dose 1 (n=107,126,233)328 (201.4 to 535.5)123 (79.6 to 191.4)193 (139.0 to 269.2)
Serotype 14: After 13vPnC Dose 1 (n=107,126,233)3571 (2772.2 to 4600.1)1277 (944.9 to 1725.8)2048 (1660.8 to 2524.9)
Serotype 18C: Before 13vPnC Dose 1 (n=95,120,215)42 (21.9 to 79.0)25 (15.5 to 39.6)31 (21.2 to 45.8)
Serotype 18C: After 13vPnC Dose 1 (n=95,120,215)2821 (1891.1 to 4208.9)1031 (671.3 to 1584.6)1609 (1188.2 to 2178.5)
Serotype 19A: Before 13vPnC Dose 1 (n=129,128,257)28 (19.1 to 40.8)23 (16.7 to 32.7)26 (19.9 to 32.9)
Serotype 19A: After 13vPnC Dose 1 (n=129,128,257)506 (381.9 to 671.7)390 (275.2 to 552.8)445 (355.7 to 555.9)
Serotype 19F: Before 13vPnC Dose 1 (n=123,123,246)11 (7.6 to 15.5)14 (9.5 to 20.1)12 (9.5 to 15.8)
Serotype 19F: After 13vPnC Dose 1 (n=123,123,246)425 (285.3 to 632.5)214 (130.4 to 352.3)302 (219.3 to 415.2)
Serotype 23F: Before 13vPnC Dose 1 (n=118,125,243)14 (9.3 to 22.0)7 (5.3 to 9.0)10 (7.6 to 12.7)
Serotype 23F: After 13vPnC Dose 1 (n=118,125,243)587 (379.3 to 907.7)140 (86.6 to 227.6)281 (200.8 to 393.7)
Other pre-specifiedGeometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 1 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose and after 13vPnC Dose 1 blood draws.

Time frame:
Before 13vPnC Dose 1, 1 month after 13vPnC Dose 1
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 1 in Pediatric, Adult and All Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n = 129, 127, 256)9.8 (6.97 to 13.81)12.2 (8.84 to 16.84)10.9 (8.65 to 13.81)
Serotype 3 (n = 126, 128, 254)4.8 (3.72 to 6.30)4.1 (3.22 to 5.30)4.5 (3.73 to 5.35)
Serotype 4 (n = 108, 119, 227)89.4 (51.43 to 155.31)51.3 (31.16 to 84.59)66.8 (46.17 to 96.75)
Serotype 5 (n = 125, 122, 247)14.4 (9.56 to 21.67)21.7 (14.55 to 32.32)17.6 (13.25 to 23.44)
Serotype 6A (n = 99, 98, 197)22.2 (12.61 to 38.90)25.2 (14.51 to 43.83)23.6 (15.98 to 34.94)
Serotype 6B (n = 101, 120, 221)13.8 (8.12 to 23.45)9.1 (5.91 to 13.95)11.0 (7.87 to 15.37)
Serotype 7F (n = 110, 113, 223)9.1 (5.79 to 14.23)52.2 (31.42 to 86.57)22.0 (15.42 to 31.42)
Serotype 9V (n = 109, 117, 226)16.6 (9.71 to 28.47)17.8 (10.53 to 30.18)17.2 (11.87 to 25.04)
Serotype 14 (n = 107, 126, 233)10.9 (6.79 to 17.41)10.3 (6.82 to 15.70)10.6 (7.76 to 14.44)
Serotype 18C (n = 95, 120, 215)67.9 (35.25 to 130.73)41.6 (24.59 to 70.26)51.6 (34.27 to 77.78)
Serotype 19A (n = 129, 128, 257)18.1 (12.52 to 26.25)16.7 (11.78 to 23.61)17.4 (13.51 to 22.38)
Serotype 19F (n = 123, 123, 246)39.0 (24.56 to 62.05)15.5 (9.77 to 24.65)24.6 (17.69 to 34.25)
Serotype 23F (n = 118, 125, 243)41.1 (24.94 to 67.81)20.2 (12.78 to 32.05)28.6 (20.34 to 40.10)
Other pre-specifiedGeometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
mcg/mL13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1: After 13vPnC Dose 3 (n=128,127,255)4.08 (3.53 to 4.73)3.94 (3.22 to 4.82)4.01 (3.54 to 4.54)
Serotype 1: After 23vPS Dose (n=128,127,255)4.42 (3.80 to 5.14)4.02 (3.32 to 4.85)4.21 (3.74 to 4.75)
Serotype 3: After 13vPnC Dose 3 (n=124,118,242)1.49 (1.27 to 1.75)1.04 (0.87 to 1.26)1.25 (1.11 to 1.42)
Serotype 3: After 23vPS Dose (n=124,118,242)1.65 (1.42 to 1.92)0.98 (0.82 to 1.17)1.28 (1.14 to 1.44)
Serotype 4: After 13vPnC Dose 3 (n=133,128,261)3.29 (2.79 to 3.87)3.19 (2.59 to 3.93)3.24 (2.84 to 3.70)
Serotype 4: After 23vPS Dose (n=133,128,261)3.28 (2.77 to 3.88)3.01 (2.44 to 3.72)3.15 (2.75 to 3.59)
Serotype 5: After 13vPnC Dose 3 (n=132,130,262)4.73 (4.02 to 5.57)5.54 (4.64 to 6.63)5.12 (4.54 to 5.78)
Serotype 5: After 23vPS Dose (n=132,130,262)5.08 (4.33 to 5.95)6.20 (5.23 to 7.35)5.61 (4.99 to 6.30)
Serotype 6A: After 13vPnC Dose 3 (n=122,129,251)8.20 (6.99 to 9.61)7.07 (5.75 to 8.69)7.60 (6.67 to 8.66)
Serotype 6A: After 23vPS Dose (n=122,129,251)7.98 (6.85 to 9.31)6.71 (5.51 to 8.17)7.30 (6.44 to 8.27)
Serotype 6B: After 13vPnC Dose 3 (n=133,129,262)12.25 (10.31 to 14.55)8.29 (6.78 to 10.13)10.10 (8.84 to 11.55)
Serotype 6B: After 23vPS Dose (n=133,129,262)11.10 (9.39 to 13.13)8.25 (6.80 to 10.01)9.59 (8.44 to 10.90)
Serotype 7F: After 13vPnC Dose 3 (n=133,130,263)5.05 (4.39 to 5.81)5.88 (4.93 to 7.02)5.44 (4.87 to 6.09)
Serotype 7F: After 23vPS Dose (n=133,130,263)5.15 (4.50 to 5.90)5.93 (5.02 to 7.00)5.52 (4.96 to 6.14)
Serotype 9V: After 13vPnC Dose 3 (n=133,130,263)5.02 (4.40 to 5.72)5.49 (4.59 to 6.57)5.25 (4.70 to 5.86)
Serotype 9V: After 23vPS Dose (n=133,130,263)5.27 (4.62 to 6.00)5.83 (4.88 to 6.96)5.54 (4.96 to 6.18)
Serotype 14: After 13vPnC Dose 3 (n=133,130,263)13.18 (10.19 to 17.05)15.35 (11.97 to 19.69)14.21 (11.89 to 16.98)
Serotype 14: After 23vPS Dose (n=133,130,263)12.98 (10.10 to 16.67)16.24 (12.82 to 20.57)14.50 (12.21 to 17.21)
Serotype 18C: After 13vPnC Dose 3 (n=132,130,262)3.84 (3.21 to 4.59)5.17 (4.25 to 6.28)4.45 (3.90 to 5.08)
Serotype 18C: After 23vPS Dose (n=132,130,262)3.54 (2.98 to 4.20)4.80 (3.98 to 5.79)4.12 (3.62 to 4.68)
Serotype 19A: After 13vPnC Dose 3 (n=133,130,263)14.16 (12.21 to 16.41)13.21 (11.13 to 15.68)13.68 (12.22 to 15.31)
Serotype 19A: After 23vPS Dose (n=133,130,263)13.16 (11.31 to 15.33)13.28 (11.24 to 15.69)13.22 (11.82 to 14.79)
Serotype 19F: After 13vPnC Dose 3 (n=130,127,257)6.15 (5.09 to 7.45)5.67 (4.47 to 7.19)5.91 (5.08 to 6.87)
Serotype 19F: After 23vPS Dose (n=130,127,257)6.78 (5.65 to 8.14)5.84 (4.62 to 7.39)6.30 (5.44 to 7.30)
Serotype 23F: After 13vPnC Dose 3 (n=132,129,261)6.69 (5.60 to 7.98)7.30 (5.87 to 9.09)6.98 (6.07 to 8.03)
Serotype 23F: After 23vPS Dose (n=132,129,261)5.99 (5.05 to 7.11)7.03 (5.69 to 8.70)6.49 (5.66 to 7.43)
Other pre-specifiedGeometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.

Time frame:
1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n = 128, 127, 255)1.08 (1.01 to 1.16)1.02 (0.96 to 1.08)1.05 (1.00 to 1.10)
Serotype 3 (n = 124, 118, 242)1.11 (1.03 to 1.20)0.94 (0.88 to 1.00)1.02 (0.97 to 1.08)
Serotype 4 (n = 133, 128, 261)1.00 (0.94 to 1.05)0.94 (0.90 to 0.99)0.97 (0.94 to 1.01)
Serotype 5 (n = 132, 130, 262)1.07 (1.02 to 1.13)1.12 (1.05 to 1.19)1.09 (1.05 to 1.14)
Serotype 6A (n = 122, 129, 251)0.97 (0.92 to 1.04)0.95 (0.91 to 0.99)0.96 (0.93 to 1.00)
Serotype 6B (n = 133, 129, 262)0.91 (0.87 to 0.95)1.00 (0.96 to 1.04)0.95 (0.92 to 0.98)
Serotype 7F (n = 133, 130, 263)1.02 (0.97 to 1.07)1.01 (0.95 to 1.06)1.01 (0.98 to 1.05)
Serotype 9V (n = 133, 130, 263)1.05 (1.00 to 1.10)1.06 (1.01 to 1.11)1.06 (1.02 to 1.09)
Serotype 14 (n = 133, 130, 263)0.98 (0.91 to 1.06)1.06 (0.99 to 1.13)1.02 (0.97 to 1.07)
Serotype 18C (n = 132, 130, 262)0.92 (0.88 to 0.96)0.93 (0.89 to 0.97)0.92 (0.90 to 0.95)
Serotype 19A (n = 133, 130, 263)0.93 (0.89 to 0.97)1.01 (0.96 to 1.05)0.97 (0.94 to 1.00)
Serotype 19F (n = 130, 127, 257)1.10 (1.04 to 1.17)1.03 (0.97 to 1.09)1.07 (1.02 to 1.11)
Serotype 23F (n = 132, 129, 261)0.90 (0.86 to 0.94)0.96 (0.91 to 1.02)0.93 (0.89 to 0.96)
Other pre-specifiedSerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of pediatric, adult and all participants using a mcOPA assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for both after 13vPnC Dose 3 and after 23vPS Dose blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
Reported as:
Geometric mean · titers
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC Dose 3 and 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
titers13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1: After 13vPnC Dose 3 (n=131,125,256)70 (53.4 to 93.0)67 (50.2 to 90.6)69 (56.4 to 84.3)
Serotype 1: After 23vPS Dose (n=131,125,256)100 (76.6 to 130.3)66 (49.0 to 90.2)82 (66.9 to 100.2)
Serotype 3: After 13vPnC Dose 3 (n=132,128,260)114 (94.6 to 136.7)78 (61.3 to 98.7)94 (81.1 to 109.7)
Serotype 3: After 23vPS Dose (n=132,128,260)148 (123.9 to 177.3)103 (81.6 to 130.9)124 (107.0 to 144.0)
Serotype 4: After 13vPnC Dose 3 (n=127,126,253)3213 (2698.5 to 3826.6)1888 (1427.3 to 2498.1)2466 (2087.0 to 2913.5)
Serotype 4: After 23vPS Dose (n=127,126,253)3553 (2984.9 to 4229.7)1831 (1366.0 to 2453.7)2554 (2146.3 to 3038.7)
Serotype 5: After 13vPnC Dose 3 (n=129,124,253)270 (197.0 to 370.1)143 (97.5 to 209.6)198 (154.2 to 253.5)
Serotype 5: After 23vPS Dose (n=129,124,253)378 (276.5 to 516.9)186 (130.9 to 264.4)267 (210.6 to 338.6)
Serotype 6A: After 13vPnC Dose 3 (n=132,127,259)8011 (6580.0 to 9752.1)2956 (2240.1 to 3900.3)4913 (4109.7 to 5873.6)
Serotype 6A: After 23vPS Dose (n=132,127,259)7236 (5936.2 to 8819.4)2707 (2060.8 to 3556.3)4468 (3743.3 to 5333.1)
Serotype 6B: After 13vPnC Dose 3 (n=130,126,256)7102 (5853.9 to 8615.8)3666 (2720.7 to 4940.5)5129 (4283.9 to 6141.0)
Serotype 6B: After 23vPS Dose (n=130,126,256)6652 (5460.8 to 8102.8)3324 (2496.6 to 4426.2)4728 (3961.1 to 5643.2)
Serotype 7F: After 13vPnC Dose 3 (n=131,125,256)4640 (3915.9 to 5497.9)2821 (2283.2 to 3484.4)3639 (3171.6 to 4174.8)
Serotype 7F: After 23vPS Dose (n=131,125,256)5260 (4470.4 to 6189.9)3027 (2455.7 to 3731.3)4016 (3508.3 to 4597.9)
Serotype 9V: After 13vPnC Dose 3 (n=127,125,252)4501 (3606.4 to 5618.0)1980 (1394.6 to 2811.7)2995 (2424.2 to 3700.8)
Serotype 9V: After 23vPS Dose (n=127,125,252)5114 (4090.6 to 6393.0)2037 (1452.6 to 2857.6)3240 (2629.5 to 3991.2)
Serotype 14: After 13vPnC Dose 3 (n=127,126,253)4023 (3317.5 to 4879.5)1431 (1115.7 to 1836.1)2405 (2030.8 to 2847.1)
Serotype 14: After 23vPS Dose (n=127,126,253)4718 (3861.6 to 5764.9)1620 (1284.5 to 2043.0)2771 (2346.9 to 3270.7)
Serotype 18C: After 13vPnC Dose 3 (n=129,121,250)5455 (4401.5 to 6761.4)1667 (1172.5 to 2370.8)3074 (2479.2 to 3810.5)
Serotype 18C: After 23vPS Dose (n=129,121,250)6468 (5341.1 to 7832.2)1835 (1328.1 to 2535.5)3515 (2878.5 to 4292.8)
Serotype 19A: After 13vPnC Dose 3 (n=131,125,256)1021 (837.5 to 1245.6)603 (456.7 to 796.3)790 (665.2 to 937.4)
Serotype 19A: After 23vPS Dose (n=131,125,256)1244 (1012.1 to 1529.5)691 (531.0 to 898.6)933 (788.2 to 1105.5)
Serotype 19F: After 13vPnC Dose 3 (n=126,117,243)1166 (884.3 to 1537.7)564 (375.0 to 848.1)822 (642.8 to 1051.0)
Serotype 19F: After 23vPS Dose (n=126,117,243)1696 (1296.5 to 2217.5)790 (547.5 to 1139.7)1174 (934.2 to 1474.8)
Serotype 23F: After 13vPnC Dose 3 (n=128,126,254)2346 (1883.3 to 2922.6)650 (435.3 to 969.9)1241 (976.6 to 1576.7)
Serotype 23F: After 23vPS Dose (n=128,126,254)2595 (2143.3 to 3141.5)580 (386.1 to 871.8)1234 (970.1 to 1570.3)
Other pre-specifiedSerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 23vPS Dose were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC Dose 3 and 1 month after 23vPS Dose blood draws.

Time frame:
1 month after 13vPnC Dose 3, 1 month after 23vPS Dose
Reported as:
Geometric mean · fold rise
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From 1 Month After 13vPnC Dose 3 to 1 Month After 23vPS Dose in Pediatric, Adult and All Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n = 131, 125, 256)1.4 (1.23 to 1.63)1.0 (0.86 to 1.13)1.2 (1.08 to 1.31)
Serotype 3 (n = 132, 128, 260)1.3 (1.15 to 1.48)1.3 (1.17 to 1.51)1.3 (1.20 to 1.44)
Serotype 4 (n = 127, 126, 253)1.1 (1.04 to 1.18)1.0 (0.87 to 1.09)1.0 (0.97 to 1.10)
Serotype 5 (n = 129, 124, 253)1.4 (1.15 to 1.71)1.3 (1.13 to 1.50)1.4 (1.20 to 1.53)
Serotype 6A (n = 132, 127, 259)0.9 (0.85 to 0.96)0.9 (0.86 to 0.97)0.9 (0.87 to 0.95)
Serotype 6B (n = 130, 126, 256)0.9 (0.87 to 1.01)0.9 (0.79 to 1.04)0.9 (0.86 to 0.99)
Serotype 7F (n = 131, 125, 256)1.1 (1.06 to 1.21)1.1 (0.93 to 1.23)1.1 (1.02 to 1.19)
Serotype 9V (n = 127, 125, 252)1.1 (1.05 to 1.23)1.0 (0.84 to 1.27)1.1 (0.97 to 1.21)
Serotype 14 (n = 127, 126, 253)1.2 (1.07 to 1.28)1.1 (1.03 to 1.24)1.2 (1.08 to 1.23)
Serotype 18C (n = 129, 121, 250)1.2 (1.04 to 1.35)1.1 (0.92 to 1.31)1.1 (1.03 to 1.27)
Serotype 19A (n = 131, 125, 256)1.2 (1.11 to 1.34)1.1 (1.03 to 1.27)1.2 (1.10 to 1.27)
Serotype 19F (n = 126, 117, 243)1.5 (1.25 to 1.69)1.4 (1.14 to 1.72)1.4 (1.26 to 1.62)
Serotype 23F (n = 128, 126, 254)1.1 (0.96 to 1.28)0.9 (0.81 to 0.98)1.0 (0.91 to 1.09)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters (cm) for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged greater than (\>) 12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Report of severe swelling was confirmed as data entry error.

Time frame:
Within 14 days after 13vPnC Dose 1
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 1
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Redness: Any (n = 92, 88, 180)20.72.311.7
Redness: Mild (n = 91, 88, 179)19.82.311.2
Redness: Moderate (n = 85, 88, 173)2.40.01.2
Redness: Severe (n = 84, 88, 172)0.00.00.0
Swelling: Any (n = 97, 94, 191)29.99.619.9
Swelling: Mild (n = 91, 93, 184)17.68.613.0
Swelling: Moderate (n = 92, 89, 181)16.31.18.8
Swelling: Severe (n = 84, 88, 172)1.20.00.6
Pain at Injection Site: Any (n = 117, 121, 238)68.462.865.5
Pain at Injection Site: Mild (n = 112, 116, 228)55.456.055.7
Pain at Injection Site: Moderate (n = 94, 94, 188)28.718.123.4
Pain at Injection Site: Severe (n = 86, 89, 175)8.12.25.1
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

Time frame:
Within 14 days after 13vPnC Dose 2
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 2
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Redness: Any (n = 101, 86, 187)13.92.38.6
Redness: Mild (n = 100, 86, 186)10.02.36.5
Redness: Moderate (n = 95, 85, 180)4.20.02.2
Redness: Severe (n = 93, 85, 178)1.10.00.6
Swelling: Any (n = 103, 88, 191)25.28.017.3
Swelling: Mild (n = 102, 88, 190)18.68.013.7
Swelling: Moderate (n = 99, 85, 184)12.10.06.5
Swelling: Severe (n = 93, 85, 178)0.00.00.0
Pain at Injection Site: Any (n = 117, 119, 236)60.779.870.3
Pain at Injection Site: Mild (n = 110, 117, 227)49.172.661.2
Pain at Injection Site: Moderate (n= 103, 96, 199)24.327.125.6
Pain at Injection Site: Severe (n = 93, 86, 179)5.43.54.5
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 cm for participants aged 6 to \<12 years and 2.5 to 5.0 cm for participants aged \>12 years); Moderate (2.5 to 7.0 cm for participants aged 6 to \<12 years and 5.1 to 10.0 cm for participants aged \>12 years); Severe (\>7 cm for participants aged 6 to \<12 years and \>10 cm for participants aged \>12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

Time frame:
Within 14 days after 13vPnC Dose 3
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Local Reactions: 13vPnC Dose 3
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Redness: Any (n = 84, 70, 154)8.30.04.5
Redness: Mild (n = 83, 70, 153)7.20.03.9
Redness: Moderate (n = 82, 70, 152)2.40.01.3
Redness: Severe (n = 80, 70, 150)0.00.00.0
Swelling: Any (n = 89, 71, 160)18.04.211.9
Swelling: Mild (n = 86, 71, 157)10.54.27.6
Swelling: Moderate (n = 84, 70, 154)9.50.05.2
Swelling: Severe (n = 80, 70, 150)0.00.00.0
Pain at Injection Site: Any (n = 104, 109, 213)52.969.761.5
Pain at Injection Site: Mild (n = 96, 105, 201)41.763.853.2
Pain at Injection Site: Moderate (n = 89, 78, 167)19.124.421.6
Pain at Injection Site: Severe (n = 83, 73, 156)4.85.55.1
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1

Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C except 2 participants and all reporting of severe vomiting, after 13vPnC Dose 1, were confirmed as data entry errors.

Time frame:
Within 14 days after 13vPnC Dose 1
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 1
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Fever: >=38 degrees C (n= 94, 95, 189)19.117.918.5
Fever: >=38, <38.5 degrees C (n = 87, 92, 179)8.08.78.4
Fever: >=38.5, <39 degrees C (n = 85, 89, 174)2.43.42.9
Fever: >=39, =<40 degrees C (n = 86, 88, 174)4.72.33.4
Fever: >40 degrees C (n = 88, 93, 181)6.88.67.7
Fatigue: Any (n = 111, 119, 230)47.758.853.5
Fatigue: Mild (n = 105, 113, 218)33.351.342.7
Fatigue: Moderate (n = 96, 99, 195)26.028.327.2
Fatigue: Severe (n = 86, 92, 178)9.38.79.0
Headache: Any (n = 107, 113, 220)39.361.150.5
Headache: Mild (n = 100, 109, 209)33.057.845.9
Headache: Moderate (n = 94, 97, 191)18.122.720.4
Headache: Severe (n = 87, 89, 176)6.99.08.0
Vomiting: Any (n = 89, 91, 180)18.07.712.8
Vomiting: Mild (n = 89, 91, 180)14.67.711.1
Vomiting: Moderate (n = 84, 88, 172)2.40.01.2
Vomiting: Severe (n = 85, 88, 173)2.40.01.2
Diarrhea: Any (n = 94, 105, 199)25.534.330.2
Diarrhea: Mild (n = 92, 104, 196)19.629.825.0
Diarrhea: Moderate (n = 86, 91, 177)8.17.77.9
Diarrhea: Severe (n = 85, 88, 173)1.21.11.2
Muscle Pain: Any (n = 108, 118, 226)48.162.755.8
Muscle Pain: Mild (n = 103, 110, 213)36.956.446.9
Muscle Pain: Moderate (n = 89, 98, 187)19.119.419.3
Muscle Pain: Severe (n = 86, 91, 177)5.85.55.6
Joint Pain: Any (n = 100, 105, 205)34.042.938.5
Joint Pain: Mild (n = 98, 101, 199)26.536.631.7
Joint Pain: Moderate (n = 89, 95, 184)12.417.915.2
Joint Pain: Severe (n = 84, 91, 175)4.84.44.6
Use of Medication to Treat Pain (n = 101, 96, 197)33.724.028.9
Use of Medication to Treat Fever (n=112, 107, 219)44.639.342.0
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2

Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C and all reporting of severe vomiting, after 13vPnC Dose 2, were confirmed as data entry errors.

Time frame:
Within 14 days after 13vPnC Dose 2
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 2
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Fever: >=38 degrees C (n= 102, 88, 190)16.711.414.2
Fever: >=38, <38.5 degrees C (n = 96, 87, 183)7.39.28.2
Fever: >=38.5, <39 degrees C (n = 98, 85, 183)6.11.23.8
Fever: >=39, =<40 degrees C (n = 97, 87, 184)7.23.45.4
Fever: >40 degrees C (n = 95, 85, 180)1.11.21.1
Fatigue: Any (n = 106, 105, 211)33.048.640.8
Fatigue: Mild (n = 104, 103, 207)24.042.733.3
Fatigue: Moderate (n = 96, 88, 184)10.421.615.8
Fatigue: Severe (n = 95, 88, 183)7.45.76.6
Headache: Any (n = 101, 106, 207)28.749.139.1
Headache: Mild (n = 97, 102, 199)18.640.229.6
Headache: Moderate (n = 97, 93, 190)13.428.020.5
Headache: Severe (n = 94, 88, 182)2.13.42.7
Vomiting: Any (n = 96, 89, 185)10.410.110.3
Vomiting: Mild (n = 94, 89, 183)6.49.07.7
Vomiting: Moderate (n = 94, 85, 179)3.21.22.2
Vomiting: Severe (n = 94, 85, 179)3.20.01.7
Diarrhea: Any (n = 95, 95, 190)10.526.318.4
Diarrhea: Mild (n = 94, 93, 187)7.424.716.0
Diarrhea: Moderate (n = 93, 87, 180)3.28.05.6
Diarrhea: Severe (n = 94, 85, 179)4.31.22.8
Muscle Pain: Any (n = 112, 104, 216)37.552.944.9
Muscle Pain: Mild (n = 105, 103, 208)25.746.636.1
Muscle Pain: Moderate (n = 100, 91, 191)15.020.917.8
Muscle Pain: Severe (n = 95, 85, 180)5.32.43.9
Joint Pain: Any (n = 106, 95, 201)26.434.730.3
Joint Pain: Mild (n = 100, 93, 193)16.029.022.3
Joint Pain: Moderate (n = 99, 89, 188)11.112.411.7
Joint Pain: Severe (n = 94, 85, 179)4.32.43.4
Use of Medication to Treat Pain (n = 100, 91, 191)20.017.618.8
Use of Medication to Treat Fever (n=102, 96, 198)28.426.027.3
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3

Specific systemic events (fever \>=38 degrees Celsius\[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours). All reporting of fever \>40 degrees C except 1 participant and all reporting of severe vomiting, after 13vPnC Dose 3, were confirmed as data entry errors.

Time frame:
Within 14 days after 13vPnC Dose 3
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-Specified Systemic Events: 13vPnC Dose 3
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Fever: >=38 degrees C (n= 85, 73, 158)10.611.010.8
Fever: >=38, <38.5 degrees C (n = 82, 73, 155)6.15.55.8
Fever: >=38.5, <39 degrees C (n = 81, 72, 153)2.55.63.9
Fever: >=39, =<40 degrees C (n = 82, 70, 152)2.42.92.6
Fever: >40 degrees C (n = 83, 70, 153)3.61.42.6
Fatigue: Any (n = 92, 91, 183)25.047.336.1
Fatigue: Mild (n = 89, 88, 177)20.239.829.9
Fatigue: Moderate (n = 83, 80, 163)6.025.015.3
Fatigue: Severe (n = 83, 73, 156)4.88.26.4
Headache: Any (n = 88, 89, 177)18.246.132.2
Headache: Mild (n = 84, 87, 171)10.741.426.3
Headache: Moderate (n = 83, 77, 160)8.419.513.8
Headache: Severe (n = 82, 72, 154)3.76.95.2
Vomiting: Any (n = 85, 74, 159)8.29.58.8
Vomiting: Mild (n = 84, 72, 156)7.15.66.4
Vomiting: Moderate (n = 82, 73, 155)2.45.53.9
Vomiting: Severe (n = 81, 72, 153)1.22.82.0
Diarrhea: Any (n = 81, 81, 162)4.928.416.7
Diarrhea: Mild (n = 81, 79, 160)4.925.315.0
Diarrhea: Moderate (n = 80, 73, 153)1.36.83.9
Diarrhea: Severe (n = 81, 73, 154)1.24.12.6
Muscle Pain: Any (n = 99, 92, 191)37.447.842.4
Muscle Pain: Mild (n = 93, 89, 182)25.837.131.3
Muscle Pain: Moderate (n = 85, 78, 163)12.924.418.4
Muscle Pain: Severe (n = 84, 72, 156)8.35.67.1
Joint Pain: Any (n = 91, 83, 174)24.232.528.2
Joint Pain: Mild (n = 88, 82, 170)15.928.021.8
Joint Pain: Moderate (n = 82, 77, 159)7.315.611.3
Joint Pain: Severe (n = 81, 71, 152)2.52.82.6
Use of Medication to Treat Pain (n = 90, 79, 169)17.821.519.5
Use of Medication to Treat Fever (n = 89, 75, 164)20.220.020.1

Adverse events

Collected over Informed consent through 6-month follow-up after 13vPnC Dose 3. Local reactions and systemic events assessed within 14 days after: 13vPnC Dose 1 (Day 1); 13vPnC Dose 2 (28-42 days after 13vPnC Dose 1); and 13vPnC Dose 3 (28-42 days after 13vPnC Dose 2). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prior 13vPnC Dose 1—1/301 (0.3%)16/301 (5.3%)
13vPnC Dose 1—1/301 (0.3%)216/301 (71.8%)
13vPnC Dose 2—4/290 (1.4%)171/290 (59%)
13vPnC Dose 3—1/286 (0.3%)137/286 (47.9%)
23vPS Dose—0/282 (0%)31/282 (11%)
Follow-up—1/282 (0.4%)2/282 (0.7%)
Most frequent serious events
Most frequent serious events
EventPrior 13vPnC Dose 113vPnC Dose 113vPnC Dose 213vPnC Dose 323vPS DoseFollow-up
Pharyngitis bacterialInfections and infestations0/3010/3011/2900/2860/2821/282
Road traffic accidentInjury, poisoning and procedural complications0/3010/3010/2901/2860/2820/282
HaemorrhoidsGastrointestinal disorders0/3010/3011/2900/2860/2820/282
Lobar pneumoniaInfections and infestations0/3010/3011/2900/2860/2820/282
TonsillitisInfections and infestations0/3010/3011/2900/2860/2820/282
ConvulsionNervous system disorders0/3011/3010/2900/2860/2820/282
LymphadenopathyBlood and lymphatic system disorders1/3010/3010/2900/2860/2820/282
Croup infectiousInfections and infestations1/3010/3010/2900/2860/2820/282
Most frequent other events
Showing 10 of 116
Most frequent other events
EventPrior 13vPnC Dose 113vPnC Dose 113vPnC Dose 213vPnC Dose 323vPS DoseFollow-up
Pain at injection site (Any)Skin and subcutaneous tissue disorders—156/238166/236131/213——
Pain at injection site (Mild)Skin and subcutaneous tissue disorders—127/228139/227107/201——
Muscle pain (Any)General disorders—126/22697/21681/191——
Fatigue (Any)General disorders—123/23086/21166/183——
Headache (Any)General disorders—111/22081/20757/177——
Muscle pain (Mild)General disorders—100/21375/20857/182——
Headache (Mild)General disorders—96/20959/19945/171——
Fatigue (Mild)General disorders—93/21869/20753/177——
Joint pain (Any)General disorders—79/20561/20149/174——
Joint pain (Mild)General disorders—63/19943/19337/170——

Baseline characteristics

Safety population included all enrolled participants who received at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(years)13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)Total
Mean10.3 ± 3.0441.2 ± 8.4525.8 ± 16.72
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)Total
Female7688164
Male7463137
08

Study locations

11 sites
  • Pfizer Investigational Site
    Bucuresti, 021105, Romania
  • Pfizer Investigational Site
    Bucuresti, 030303, Romania
  • Pfizer Investigational Site
    Constanta, 900709, Romania
  • Pfizer Investigational Site
    Johannesburg, Gauteng 2013, South Africa
  • Pfizer Investigational Site
    Pretoria, Gauteng 0083, South Africa
  • Pfizer Investigational Site
    Pretoria, Gauteng 0122, South Africa
  • Pfizer Investigational Site
    Soweto, Gauteng 1818, South Africa
  • Pfizer Investigational Site
    Dundee, KwaZulu-Natal 3000, South Africa
  • Pfizer Investigational Site
    Worcester, Western Cape 6850, South Africa
  • Pfizer Investigational Site
    Bloemfontein, 9301, South Africa
  • Pfizer Investigational Site
    Paarl, 7626, South Africa
09

References and documents

Publications

  • Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015 Jul 17;29(11):1345-54. doi: 10.1097/QAD.0000000000000689. PubMed 25888646 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2009
First posted
Aug 20, 2009
Start
Mar 2010
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results first posted
Nov 17, 2014
Last update
Nov 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00962780
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 20, 2009
Start date
Mar 2010
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
Nov 17, 2014
Last update
Nov 17, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion